Hologic, Inc.  Notes to Consolidated Financial Statements (continued) (In thousands, except per share data) Determination of the Measurement Date for the Market Price of Acquirer Securities Issued in a Purchase Business Combination.
The components and allocation of the purchase price, consists of the following approximate amounts:
## Table 0 ##
The Company has begun to assess and formulate a plan to restructure certain of R2’s historical activities.
As of the acquisition date the Company recorded a liability of approximately $798 in accordance with EITF Issue No.95-3, Recognition of Liabilities in Connection with a Purchase Business Combination, related to the termination of certain employees and loss related to the abandonment of certain lease space under this plan of which approximately $46 has been paid as of September 30, 2006.
The Company believes this plan will be finalized within one year from the acquisition date and will record any additional liabilities at such time resulting in an increase to goodwill.
The final purchase price allocations will be completed within one year of the acquisition and any adjustments are not expected to have a material impact on the Company’s financial position or results of operation.
As part of the purchase price allocation, all intangible assets that were a part of the acquisition were identified and valued.
It was determined that only customer relationships, trademarks and developed technology had separately identifiable values.
Customer relationships represent R2’s strong active customer base, dominant market position and strong partnership with several large companies.
Trademarks represent the R2 product names that the Company intends to continue to use.
Developed technology represents currently marketable purchased products that the Company continues to resell as well as utilize to enhance and incorporate into the Company’s existing products.
The estimated $10,200 of purchase price allocated to in-process research and development projects primarily related to R2s Digital CAD products.
The projects are expected to add direct digital algorithm capabilities as well as a new platform technology to analyze images and breast density measurement.
The project is approximately 20% complete and the Company expects to spend approximately $3,100 over the year to complete.
The deferred income tax asset relates to the tax effect of acquired net operating loss carry forwards that the Company believes are realizable partially offset by acquired identifiable intangible assets, and fair value adjustments to acquired inventory as such amounts are not deductible for tax purposes.
Acquisition of Suros Surgical Systems, Inc.  On July 27, 2006, the Company completed the acquisition of Suros Surgical Systems, Inc. , pursuant to an Agreement and Plan of Merger dated April 17, 2006.
The results of operations for Suros have been included in the Company’s consolidated financial statements from the date of acquisition as part of its Mammography business segment.
Suros Surgical, located in Indianapolis, Indiana, develops, manufactures and sells minimally invasive interventional breast biopsy technology and products for biopsy, tissue removal and biopsy site marking.
Hologic, Inc.  Notes to Consolidated Financial Statements (continued) (In thousands, except per share data) The Company has considered the provision of EITF Issue No.95-8, Accounting for Contingent Consideration Paid to the Shareholders of and Acquired Enterprise in a Purchase Business Combination, and concluded that this contingent consideration represents additional purchase price.
During the fourth quarter of fiscal 2007 the Company paid approximately $19,000 to former Suros shareholders for the first annual earn-out period resulting in an increase to goodwill for the same amount.
Goodwill will be increased by the amount of the additional consideration, if any, when it becomes due and payable for the second annual earn-out.
In addition to the earn-out discussed above, the Company increased goodwill related to the Suros acquisition in the amount of $210 during the year ended September 29, 2007.
The increase was primarily related to recording a liability of approximately $550 in accordance with EITF 95-3 related to the termination of certain employees who have ceased all services for the Company.
Approximately $400 of this liability was paid during the year ended September 29, 2007 and the balance is expected to be paid by the end of the second quarter of fiscal 2008.
This increase was partially offset by a decrease to goodwill as a result of a change in the valuation of certain assets and liabilities acquired based on information received during the year ended September 29, 2007.
There have been no other material changes to purchase price allocations as disclosed in the Company’s Form 10-K for the year ended September 30, 2006.
As part of the purchase price allocation, all intangible assets that were a part of the acquisition were identified and valued.
It was determined that only customer relationship, trade name, developed technology and know how and in-process research and development had separately identifiable values.
Customer relationship represents Suros large installed base that are expected to purchase disposable products on a regular basis.
Trade name represent the Suros product names that the Company intends to continue to use.
Developed technology and know how represents currently marketable purchased products that the Company continues to resell as well as utilize to enhance and incorporate into the Company’s existing products.
The estimated $4,900 of purchase price allocated to in-process research and development projects primarily related to Suros’ disposable products.
The projects were at various stages of completion and include next generation handpiece and site marker technologies.
The Company has continued to work on these projects and expects they will be completed during fiscal 2008.
The deferred income tax liability relates to the tax effect of acquired identifiable intangible assets, and fair value adjustments to acquired inventory as such amounts are not deductible for tax purposes, partially offset by acquired net operating loss carry forwards that the Company believes are realizable.
For all of the acquisitions discussed above, goodwill represents the excess of the purchase price over the net identifiable tangible and intangible assets acquired.
The Company determined that the acquisition of each AEG, BioLucent, R2 and Suros resulted in the recognition of goodwill primarily because of synergies unique to the Company and the strength of its acquired workforce.
Supplemental Unaudited Pro-forma Information The following unaudited pro forma information presents the consolidated results of operations of the Company, R2 and Suros as if the acquisitions had occurred at the beginning of fiscal 2006, with pro forma adjustments to give effect to amortization of intangible assets, an increase in interest expense on acquisition financing and certain other adjustments together with related tax effects:
## Table 1 ##
Hologic, Inc.  Notes to Consolidated Financial Statements (continued) (In thousands, except per share data) 3.  Business Combinations Fiscal 2008 Acquisitions: Acquisition of Third Wave Technologies, Inc.  On July 24, 2008 the Company completed its acquisition of Third Wave Technologies, Inc.  (“Third Wave”) pursuant to a definitive agreement dated June 8, 2008.
The Company has concluded that the acquisition of Third Wave does not represent a material business combination and therefore no pro forma financial information has been provided herein.
Subsequent to the acquisition date, the Company’s results of operations include the results of Third Wave, which has been reported as a component of the Company’s Diagnostics reporting segment.
Third Wave, located in Madison, Wisconsin, develops and markets molecular diagnostic reagents for a wide variety of DNA and RNA analysis applications based on its proprietary Invader chemistry.
Third Wave’s current clinical diagnostic offerings consist of products for conditions such as Cystic Fibrosis, Hepatitis C, cardiovascular risk and other diseases.
Third Wave recently submitted to the U. S.  Food and Drug Administration (“FDA”) pre-market approval (“PMA”) applications for two human papillomavirus (“HPV”) tests.
The Company paid $11.25 per share of Third Wave, for an aggregate purchase price of approximately $591,200 (subject to adjustment) consisting of approximately $575,400 in cash in exchange for stock and warrants; approximately 668 of fully vested stock options granted to Third Wave employees in exchange for their vested Third Wave stock options, with an estimated fair value of approximately $8,100; and approximately $7,700 for acquisition related fees and expenses.
There are no potential contingent consideration arrangements payable to the former shareholders in connection with this transaction.
Additionally, the Company granted approximately 315 unvested stock options in exchange for unvested Third Wave stock options, with an estimated fair value of approximately $5,100, which will be recognized as compensation expense over the vesting period.
The Company determined the fair value of the options issued in connection with the acquisition in accordance with EITF Issue No.99-12, Determination of the Measurement Date for the Market Price of Acquirer Securities Issued in a Purchase Business Combination”).
The Company determined the measurement date to be July 24, 2008, the date the transaction was completed, as the number of shares to be issued according to the exchange ratio was not fixed until this date.
The Company valued the securities based on the average market price for two days before the measurement date and the measurement date itself.
The weighted average stock price was determined to be approximately $23.54.
The preliminary purchase price is as follows:
## Table 2 ##
The purchase price of $148.4 million was comprised of $135.0 million in cash, of which $100.0 million was paid up-front and $35.0 million plus a working capital adjustment of $13.2 million, was deferred for one year.
In addition, $0.9 million was paid in the first quarter of fiscal 2012 for additional assets acquired.
The deferred payment was recorded on a present value basis of $47.5 million in purchase accounting to reflect fair value, and such payment was accreted through interest expense over the one year deferral period.
The $35.0 million and a portion of the working capital adjustment of $8.5 million were paid in the fourth quarter of fiscal 2012.
As agreed to by the parties, the remainder is due after the completion of fiscal 2013.
In addition, the majority of the former shareholders of TCT were eligible to receive two annual contingent earn-out payments (subject to adjustment) not to exceed $200.0 million less the deferred payment.
The contingent earn-out payments were based on a multiple of incremental revenue growth for the one year periods beginning January 1, 2011 and January 1, 2012 as compared to the respective prior year periods, and were payable after the first and second anniversaries from the date of acquisition, respectively.
Since these payments were contingent on future employment, they were recognized as compensation expense ratably over the required service periods.
Based on actual and projected revenues for the TCT business, the Company recorded compensation expense of $80.0 million, $75.5 million and $17.6 million in fiscal 2013, 2012 and 2011, respectively.
In the third quarter of fiscal 2012, the first measurement period was completed, and the Company paid the earned contingent consideration of $54.0 million in the fourth quarter of fiscal 2012.
The second earn-out period was completed in the third quarter of fiscal 2013, and the Company paid $87.4 million in the fourth quarter of fiscal 2013.
As of September 28, 2013, the Company had accrued $31.7 million, which the Company paid in November 2013.
The Company did not issue any equity awards in connection with this acquisition, and third-party transaction costs were not significant.
The allocation of the purchase price was based on estimates of the fair value of assets acquired and liabilities assumed as of June 1, 2011.
The components of the purchase price allocation consisted of the following:
## Table 3 ##
In connection with the purchase price allocation, the Company determined that the separately identifiable intangible assets were customer relationships, business licenses, and trade names related to the TCT company name.
The fair value of the intangible assets was determined through the application of the income approach, and the cash flow projections were discounted at 12.5%.
Customer relationships relate to relationships that TCT’s founders and sales force have developed with obstetricians, gynecologists, hospitals, and clinical laboratories.
Customer relationships, business licenses and trade names are being amortized over a weighted average period of 12.7 years, 10 years and 12 years, respectively.
The excess of the purchase price over the fair value of the tangible net assets and intangible assets acquired was recorded to goodwill.
The goodwill recognized is attributable to the established sales and distribution network of TCT and expected synergies that the Company will realize from this acquisition.
None of the goodwill is expected to be deductible for income tax purposes.
Table of Contents Fiscal Year Ended September 29, 2012 Compared to Fiscal Year Ended September 24, 2011 Product Sales.
## Table 4 ##
In fiscal 2012, Breast Health product revenues increased 4% compared to fiscal 2011 primarily due to the increase in our breast biopsy products revenue of $18.5 million as a result of an increase in the number of Eviva and Celero biopsy devices sold in the United States.
In addition, our digital mammography systems revenue increased $1.4 million in fiscal 2012 compared to fiscal 2011 primarily attributable to an increase in the number of units sold of both of our 2D and 3D Dimensions products worldwide, partially offset by slightly lower average selling prices internationally in fiscal 2012.
Partially offsetting the increase in revenues from the Dimensions systems was a decrease in the number of Selenia systems sold worldwide and, to a lesser extent, a slight deterioration of average selling prices, and a continued shift in Selenia product mix and configuration differences.
We sold more Selenia Performance models, which have fewer features than our base Selenia model, which is a full-featured model, and carry lower average selling prices.
In addition, we sold more Selenia systems internationally as a percentage of total Selenia systems, and average selling prices were lower in our international markets compared to the domestic market.
We also had an additional $5.0 million in revenue in fiscal 2012 from our new Trident product.
Diagnostics product sales increased 25% in fiscal 2012 compared to fiscal 2011 primarily due to the inclusion of Gen-Probe, which contributed $86.7 million in revenue, and an increase of $29.7 million in ThinPrep pap tests revenue.
The ThinPrep increase was principally from an increase in the sales price of ThinPrep in China as well as higher volumes from the inclusion of revenues of TCT (our former distributor in that country acquired in the third quarter of fiscal 2011) and, to a lesser extent, an increase in the number of ThinPrep pap tests sold in other international markets, partially offset by a decline in domestic units sold.
The inclusion of Gen-Probe’s results is partially impacted by the Novartis collaboration.
Pursuant to the collaboration, a portion of GenProbe’s revenue is contingent on donations testing revenue earned by Novartis, however, Gen-Probe recognizes the full product cost upon shipment.
As a result, amounts to be received for this contingent revenue related to inventory on hand and not yet utilized by Novartis’ customers as of the acquisition date were recorded as unbilled accounts receivable on the balance sheet in purchase accounting and were not recorded as revenue in our results of operations.
In fiscal 2012, this contingent revenue of $11.6 million was not recognized in our results of operations.
We also experienced growth in our legacy molecular diagnostics products, which contributed a revenue increase of $13.5 million in fiscal 2012 as we continued to gain new customer accounts and unit sales to existing customers and increase our international sales through TCT.
In addition, in fiscal 2012, we sold more diagnostics instruments internationally, increasing revenue by $4.8 million.
Revenues also increased slightly due to the extra week in fiscal 2012 compared to fiscal 2011.
Fiscal 2012 was a 53-week year compared to fiscal 2011, which was a 52-week year.
GYN surgical product sales increased 4% in fiscal 2012 compared to fiscal 2011 primarily due to the inclusion of the MyoSure system, which contributed an increase of $29.7 million of revenue in fiscal 2012, partially offset by a decrease in NovaSure devices revenue of $9.0 million in fiscal 2012.
In addition, revenues also increased slightly due to the extra week in fiscal 2012 compared to fiscal 2011.
While we experienced an

<table><tr><td>Net tangible assets acquired as of July 13, 2006</td><td>$800</td></tr><tr><td>In-process research and development</td><td>10,200</td></tr><tr><td>Developed technology and know how</td><td>39,500</td></tr><tr><td>Customer relationship</td><td>15,700</td></tr><tr><td>Trade name</td><td>3,300</td></tr><tr><td>Order Backlog</td><td>800</td></tr><tr><td>Deferred income taxes</td><td>4,400</td></tr><tr><td>Goodwill</td><td>145,900</td></tr><tr><td>Estimated Purchase Price</td><td>$220,600</td></tr></table>
<table><tr><td></td><td>2006</td></tr><tr><td>Net revenue</td><td>$524,340</td></tr><tr><td>Net income</td><td>28,649</td></tr><tr><td>Net income per share—basic</td><td>$0.55</td></tr><tr><td>Net income per share—assuming dilution</td><td>$0.33</td></tr></table>
<table><tr><td>Cash portion of consideration</td><td>$575,400</td></tr><tr><td>Fair value of vested options exchanged</td><td>8,100</td></tr><tr><td>Direct acquisition costs</td><td>7,700</td></tr><tr><td>Total estimated purchase price</td><td>$591,200</td></tr></table>
<table><tr><td>Cash</td><td>$27,961</td></tr><tr><td>Accounts receivable</td><td>17,811</td></tr><tr><td>Inventory</td><td>5,301</td></tr><tr><td>Property and equipment</td><td>4,710</td></tr><tr><td>Other tangible assets</td><td>1,082</td></tr><tr><td>Accrued taxes</td><td>-14,874</td></tr><tr><td>Accounts payable and accrued expenses</td><td>-6,641</td></tr><tr><td>Customer relationships</td><td>45,780</td></tr><tr><td>Business licenses</td><td>2,500</td></tr><tr><td>Trade names</td><td>2,110</td></tr><tr><td>Deferred taxes, net</td><td>-12,473</td></tr><tr><td>Goodwill</td><td>75,161</td></tr><tr><td>Purchase Price</td><td>$148,428</td></tr></table>
<table><tr><td></td><td colspan="6"> Years Ended</td></tr><tr><td></td><td colspan="2">September 29, 2012</td><td colspan="2">September 24, 2011</td><td colspan="2"> Change</td></tr><tr><td></td><td> Amount</td><td>% of Total Revenue</td><td> Amount</td><td>% of Total Revenue</td><td> Amount</td><td> %</td></tr><tr><td><i>Product Sales</i></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Breast Health</td><td>$572,485</td><td>29%</td><td>$550,112</td><td>31%</td><td>$22,373</td><td>4%</td></tr><tr><td>Diagnostics</td><td>707,529</td><td>35%</td><td>566,349</td><td>32%</td><td>141,180</td><td>25%</td></tr><tr><td>GYN Surgical</td><td>311,643</td><td>16%</td><td>299,120</td><td>17%</td><td>12,523</td><td>4%</td></tr><tr><td>Skeletal Health</td><td>66,071</td><td>3%</td><td>62,759</td><td>3%</td><td>3,312</td><td>5%</td></tr><tr><td></td><td>$1,657,728</td><td>83%</td><td>$1,478,340</td><td>83%</td><td>$179,388</td><td>12%</td></tr></table>

Question: What is the sum of the product sales in the years where Diagnostics is greater than 700,000?